We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.
- Authors
Brody, Joshua D; Ai, Weiyun Z; Czerwinski, Debra K; Torchia, James A; Levy, Mia; Advani, Ranjana H; Kim, Youn H; Hoppe, Richard T; Knox, Susan J; Shin, Lewis K; Wapnir, Irene; Tibshirani, Robert J; Levy, Ronald
- Abstract
Combining tumor antigens with an immunostimulant can induce the immune system to specifically eliminate cancer cells. Generally, this combination is accomplished in an ex vivo, customized manner. In a preclinical lymphoma model, intratumoral injection of a Toll-like receptor 9 (TLR9) agonist induced systemic antitumor immunity and cured large, disseminated tumors.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Vol 28, Issue 28, p4324
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2010.28.9793